Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
On September 14, 2017, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals were voted on and approved by the Company’s stockholders at the Annual Meeting with the stockholders having voted as set forth below:
| Proposal 1: | To elect two Class III members of the Board of Directors of the Company, who will serve for a term of three years. |
| For | Withhold | Broker Non-Vote | |
| (a) Joseph Keegan, Ph.D | 5,736,303 | 802,908 | 9,538,190 |
| (b) Jack E. Stover | 4,995,827 | 1,543,384 | 9,538,190 |
| Proposal 2: | To conduct a non-binding advisory vote on a resolution approving the compensation of the Company’s named executive officers. |
| For | Against | Abstain | Broker Non-Vote |
| 4,494,342 | 1,919,244 | 125,625 | 9,538,190 |
| Proposal 3: | To conduct a non-binding advisory vote on a resolution to approve named executive officer compensation every one, two or three years. |
| Every One Year | Every Two Years | Every Three Years | Abstain | Broker Non-Vote |
| 2,627,223 | 220,885 | 3,506,004 | 185,099 | 9,538,190 |
| Proposal 4: | To approve an amendment to the Company’s Amended and Restated 2004 Stock Award and Incentive Plan to increase the maximum number of shares available for sale thereunder by 3,700,000 and to approve certain recent option awards. |
| For | Against | Abstain | Broker Non-Vote |
| 3,583,065 | 2,858,374 | 97,772 | 9,538,190 |
| Proposal 5: | To ratify the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. |
| For | Against | Abstain | Broker Non-Vote |
| 14,748,684 | 1,072,557 | 256,160 |
About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
